Have a feature idea you'd love to see implemented? Let us know!

EXAS Exact Sciences Corp

Price (delayed)

$53.07

Market cap

$9.82B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$11.99B

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights
EXAS's revenue is up by 12% year-on-year and by 3.1% since the previous quarter
EXAS's gross profit is up by 11% year-on-year and by 2.8% since the previous quarter
Exact Sciences's EPS has increased by 26% YoY but it has decreased by 22% from the previous quarter
The company's net income rose by 24% YoY but it fell by 22% QoQ
The company's quick ratio fell by 9% YoY
The company's debt rose by 8% YoY

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
185.08M
Market cap
$9.82B
Enterprise value
$11.99B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.05
Price to sales (P/S)
3.64
EV/EBIT
N/A
EV/EBITDA
205.92
EV/Sales
4.45
Earnings
Revenue
$2.69B
EBIT
-$185.27M
EBITDA
$58.24M
Free cash flow
$98.43M
Per share
EPS
-$1.17
Free cash flow per share
$0.53
Book value per share
$17.38
Revenue per share
$14.57
TBVPS
$13.62
Balance sheet
Total assets
$6.75B
Total liabilities
$3.54B
Debt
$2.76B
Equity
$3.21B
Working capital
$809.46M
Liquidity
Debt to equity
0.86
Current ratio
2.12
Quick ratio
1.78
Net debt/EBITDA
37.26
Margins
EBITDA margin
2.2%
Gross margin
73%
Net margin
-7.9%
Operating margin
-8.9%
Efficiency
Return on assets
-3.3%
Return on equity
-6.8%
Return on invested capital
-4.8%
Return on capital employed
-3.1%
Return on sales
-6.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
0.7%
1 week
4.2%
1 month
-23.62%
1 year
-18.53%
YTD
-28.26%
QTD
-22.09%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$2.69B
Gross profit
$1.96B
Operating income
-$240.19M
Net income
-$214.04M
Gross margin
73%
Net margin
-7.9%
The company's net margin rose by 32% YoY but it fell by 18% QoQ
The company's net income rose by 24% YoY but it fell by 22% QoQ
The operating income has declined by 24% since the previous quarter but it has increased by 10% year-on-year
The operating margin has declined by 20% since the previous quarter but it has increased by 20% year-on-year

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
3.05
P/S
3.64
EV/EBIT
N/A
EV/EBITDA
205.92
EV/Sales
4.45
Exact Sciences's EPS has increased by 26% YoY but it has decreased by 22% from the previous quarter
The stock's price to book (P/B) is 31% less than its 5-year quarterly average of 4.4 and 18% less than its last 4 quarters average of 3.7
The company's equity rose by 2.9% YoY
EXAS's price to sales (P/S) is 53% less than its 5-year quarterly average of 7.8 and 19% less than its last 4 quarters average of 4.5
EXAS's revenue is up by 12% year-on-year and by 3.1% since the previous quarter

Efficiency

How efficient is Exact Sciences business performance
Exact Sciences's ROS has increased by 37% YoY but it has decreased by 21% from the previous quarter
The company's return on invested capital rose by 33% YoY but it fell by 20% QoQ
EXAS's return on assets is up by 27% year-on-year but it is down by 22% since the previous quarter
The ROE has grown by 26% YoY but it has contracted by 21% from the previous quarter

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 91% more than the total liabilities
EXAS's current ratio is down by 12% YoY and by 2.3% QoQ
The company's quick ratio fell by 9% YoY
The company's debt is 14% lower than its equity
The company's debt rose by 8% YoY
EXAS's debt to equity is up by 4.9% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.